 Corbin Eule
Concepts (94)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 4 | 2024 | 978 | 1.920 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 4 | 2024 | 1963 | 1.260 |
Why?
| | Prostate-Specific Antigen | 2 | 2023 | 161 | 0.900 |
Why?
| | Carcinoma, Small Cell | 1 | 2024 | 172 | 0.820 |
Why?
| | Neoplasm Invasiveness | 1 | 2024 | 506 | 0.730 |
Why?
| | Cisplatin | 1 | 2024 | 345 | 0.710 |
Why?
| | Urinary Bladder Neoplasms | 1 | 2024 | 258 | 0.660 |
Why?
| | Neoadjuvant Therapy | 1 | 2024 | 465 | 0.660 |
Why?
| | Mediastinal Neoplasms | 1 | 2020 | 53 | 0.600 |
Why?
| | Coombs Test | 1 | 2018 | 5 | 0.580 |
Why?
| | Anemia, Hemolytic, Autoimmune | 1 | 2018 | 14 | 0.580 |
Why?
| | Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2018 | 76 | 0.540 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 1 | 2020 | 193 | 0.520 |
Why?
| | Practice Patterns, Physicians' | 1 | 2024 | 1371 | 0.440 |
Why?
| | Terminal Care | 1 | 2018 | 283 | 0.430 |
Why?
| | Pain | 1 | 2018 | 789 | 0.380 |
Why?
| | Palliative Care | 1 | 2018 | 1020 | 0.310 |
Why?
| | Doxorubicin | 2 | 2024 | 401 | 0.300 |
Why?
| | Aged | 9 | 2025 | 26153 | 0.300 |
Why?
| | Databases, Factual | 2 | 2024 | 1490 | 0.280 |
Why?
| | Retrospective Studies | 5 | 2024 | 17291 | 0.260 |
Why?
| | Neoplasms | 2 | 2025 | 2906 | 0.260 |
Why?
| | Neoplasms, Unknown Primary | 1 | 2025 | 20 | 0.220 |
Why?
| | Prognosis | 2 | 2024 | 4316 | 0.220 |
Why?
| | Thiohydantoins | 1 | 2024 | 5 | 0.220 |
Why?
| | Androstenes | 1 | 2024 | 16 | 0.210 |
Why?
| | Phenylthiohydantoin | 1 | 2024 | 44 | 0.210 |
Why?
| | Androgen Receptor Antagonists | 1 | 2024 | 35 | 0.210 |
Why?
| | Vinblastine | 1 | 2024 | 75 | 0.210 |
Why?
| | Cystectomy | 1 | 2024 | 42 | 0.200 |
Why?
| | Peripheral Nervous System Diseases | 1 | 2025 | 134 | 0.200 |
Why?
| | Middle Aged | 8 | 2025 | 36215 | 0.200 |
Why?
| | Androgen Antagonists | 1 | 2024 | 91 | 0.200 |
Why?
| | Aged, 80 and over | 3 | 2025 | 8333 | 0.200 |
Why?
| | Benzamides | 1 | 2024 | 226 | 0.200 |
Why?
| | Nitriles | 1 | 2024 | 207 | 0.190 |
Why?
| | Platinum | 1 | 2023 | 48 | 0.190 |
Why?
| | Methotrexate | 1 | 2024 | 233 | 0.190 |
Why?
| | Deoxycytidine | 1 | 2024 | 220 | 0.190 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2024 | 423 | 0.190 |
Why?
| | Male | 9 | 2025 | 72842 | 0.170 |
Why?
| | Humans | 13 | 2025 | 145474 | 0.170 |
Why?
| | Carcinoma, Renal Cell | 1 | 2023 | 230 | 0.160 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2022 | 382 | 0.160 |
Why?
| | Pyrazoles | 1 | 2024 | 517 | 0.160 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2022 | 440 | 0.160 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2025 | 641 | 0.160 |
Why?
| | Etoposide | 1 | 2020 | 168 | 0.150 |
Why?
| | Vincristine | 1 | 2020 | 142 | 0.150 |
Why?
| | Cyclophosphamide | 1 | 2020 | 270 | 0.150 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2022 | 454 | 0.150 |
Why?
| | Plasmablastic Lymphoma | 1 | 2019 | 8 | 0.150 |
Why?
| | Prednisone | 1 | 2020 | 224 | 0.140 |
Why?
| | Rituximab | 1 | 2020 | 210 | 0.140 |
Why?
| | Hematologic Tests | 1 | 2018 | 22 | 0.140 |
Why?
| | Kidney Neoplasms | 1 | 2023 | 413 | 0.140 |
Why?
| | Bone Cysts | 1 | 2018 | 12 | 0.130 |
Why?
| | Bone Cements | 1 | 2018 | 39 | 0.130 |
Why?
| | Paraplegia | 1 | 2018 | 60 | 0.130 |
Why?
| | Spirituality | 1 | 2018 | 87 | 0.130 |
Why?
| | Sacrum | 1 | 2018 | 80 | 0.130 |
Why?
| | Dyspnea | 1 | 2018 | 250 | 0.120 |
Why?
| | Radiation Injuries | 1 | 2018 | 149 | 0.120 |
Why?
| | Medical Oncology | 1 | 2018 | 339 | 0.110 |
Why?
| | Antineoplastic Agents | 1 | 2025 | 2214 | 0.100 |
Why?
| | Erythrocytes | 1 | 2018 | 748 | 0.090 |
Why?
| | Decision Making | 1 | 2018 | 977 | 0.080 |
Why?
| | Autoantibodies | 1 | 2018 | 1509 | 0.080 |
Why?
| | Female | 5 | 2025 | 78844 | 0.060 |
Why?
| | Adult | 4 | 2025 | 40777 | 0.060 |
Why?
| | Vinca Alkaloids | 1 | 2025 | 6 | 0.060 |
Why?
| | Bridged-Ring Compounds | 1 | 2025 | 31 | 0.060 |
Why?
| | Microsatellite Instability | 1 | 2025 | 55 | 0.060 |
Why?
| | Postoperative Complications | 1 | 2018 | 2970 | 0.050 |
Why?
| | Taxoids | 1 | 2025 | 114 | 0.050 |
Why?
| | Pharmacogenetics | 1 | 2025 | 175 | 0.050 |
Why?
| | Young Adult | 1 | 2020 | 14218 | 0.050 |
Why?
| | B7-H1 Antigen | 1 | 2025 | 244 | 0.050 |
Why?
| | Anilides | 1 | 2023 | 84 | 0.050 |
Why?
| | Adolescent | 1 | 2020 | 22529 | 0.040 |
Why?
| | Genomics | 1 | 2025 | 825 | 0.040 |
Why?
| | Pyridines | 1 | 2023 | 609 | 0.040 |
Why?
| | Genome-Wide Association Study | 1 | 2025 | 1407 | 0.030 |
Why?
| | Plasmacytoma | 1 | 2018 | 19 | 0.030 |
Why?
| | Biomarkers, Tumor | 1 | 2025 | 1321 | 0.030 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2025 | 2158 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2019 | 767 | 0.030 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2023 | 992 | 0.030 |
Why?
| | Electronic Health Records | 1 | 2025 | 1196 | 0.030 |
Why?
| | Genetic Predisposition to Disease | 1 | 2025 | 2378 | 0.030 |
Why?
| | Bone Neoplasms | 1 | 2018 | 259 | 0.030 |
Why?
| | Mutation | 1 | 2025 | 4075 | 0.030 |
Why?
| | Survival Rate | 1 | 2019 | 2090 | 0.030 |
Why?
| | Follow-Up Studies | 1 | 2019 | 5423 | 0.020 |
Why?
|
|
Eule's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|